Cargando…

Dosimetric benefits of daily treatment plan adaptation for prostate cancer stereotactic body radiotherapy

BACKGROUND: Hypofractionation is increasingly being applied in radiotherapy for prostate cancer, requiring higher accuracy of daily treatment deliveries than in conventional image-guided radiotherapy (IGRT). Different adaptive radiotherapy (ART) strategies were evaluated with regard to dosimetric be...

Descripción completa

Detalles Bibliográficos
Autores principales: Eckl, Miriam, Sarria, Gustavo R., Springer, Sandra, Willam, Marvin, Ruder, Arne M., Steil, Volker, Ehmann, Michael, Wenz, Frederik, Fleckenstein, Jens
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8335467/
https://www.ncbi.nlm.nih.gov/pubmed/34348765
http://dx.doi.org/10.1186/s13014-021-01872-9
_version_ 1783733112058937344
author Eckl, Miriam
Sarria, Gustavo R.
Springer, Sandra
Willam, Marvin
Ruder, Arne M.
Steil, Volker
Ehmann, Michael
Wenz, Frederik
Fleckenstein, Jens
author_facet Eckl, Miriam
Sarria, Gustavo R.
Springer, Sandra
Willam, Marvin
Ruder, Arne M.
Steil, Volker
Ehmann, Michael
Wenz, Frederik
Fleckenstein, Jens
author_sort Eckl, Miriam
collection PubMed
description BACKGROUND: Hypofractionation is increasingly being applied in radiotherapy for prostate cancer, requiring higher accuracy of daily treatment deliveries than in conventional image-guided radiotherapy (IGRT). Different adaptive radiotherapy (ART) strategies were evaluated with regard to dosimetric benefits. METHODS: Treatments plans for 32 patients were retrospectively generated and analyzed according to the PACE-C trial treatment scheme (40 Gy in 5 fractions). Using a previously trained cycle-generative adversarial network algorithm, synthetic CT (sCT) were generated out of five daily cone-beam CT. Dose calculation on sCT was performed for four different adaptation approaches: IGRT without adaptation, adaptation via segment aperture morphing (SAM) and segment weight optimization (ART1) or additional shape optimization (ART2) as well as a full re-optimization (ART3). Dose distributions were evaluated regarding dose-volume parameters and a penalty score. RESULTS: Compared to the IGRT approach, the ART1, ART2 and ART3 approaches substantially reduced the V(37Gy)(bladder) and V(36Gy)(rectum) from a mean of 7.4cm(3) and 2.0cm(3) to (5.9cm(3), 6.1cm(3), 5.2cm(3)) as well as to (1.4cm(3), 1.4cm(3), 1.0cm(3)), respectively. Plan adaptation required on average 2.6 min for the ART1 approach and yielded doses to the rectum being insignificantly different from the ART2 approach. Based on an accumulation over the total patient collective, a penalty score revealed dosimetric violations reduced by 79.2%, 75.7% and 93.2% through adaptation. CONCLUSION: Treatment plan adaptation was demonstrated to adequately restore relevant dose criteria on a daily basis. While for SAM adaptation approaches dosimetric benefits were realized through ensuring sufficient target coverage, a full re-optimization mainly improved OAR sparing which helps to guide the decision of when to apply which adaptation strategy.
format Online
Article
Text
id pubmed-8335467
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-83354672021-08-04 Dosimetric benefits of daily treatment plan adaptation for prostate cancer stereotactic body radiotherapy Eckl, Miriam Sarria, Gustavo R. Springer, Sandra Willam, Marvin Ruder, Arne M. Steil, Volker Ehmann, Michael Wenz, Frederik Fleckenstein, Jens Radiat Oncol Research BACKGROUND: Hypofractionation is increasingly being applied in radiotherapy for prostate cancer, requiring higher accuracy of daily treatment deliveries than in conventional image-guided radiotherapy (IGRT). Different adaptive radiotherapy (ART) strategies were evaluated with regard to dosimetric benefits. METHODS: Treatments plans for 32 patients were retrospectively generated and analyzed according to the PACE-C trial treatment scheme (40 Gy in 5 fractions). Using a previously trained cycle-generative adversarial network algorithm, synthetic CT (sCT) were generated out of five daily cone-beam CT. Dose calculation on sCT was performed for four different adaptation approaches: IGRT without adaptation, adaptation via segment aperture morphing (SAM) and segment weight optimization (ART1) or additional shape optimization (ART2) as well as a full re-optimization (ART3). Dose distributions were evaluated regarding dose-volume parameters and a penalty score. RESULTS: Compared to the IGRT approach, the ART1, ART2 and ART3 approaches substantially reduced the V(37Gy)(bladder) and V(36Gy)(rectum) from a mean of 7.4cm(3) and 2.0cm(3) to (5.9cm(3), 6.1cm(3), 5.2cm(3)) as well as to (1.4cm(3), 1.4cm(3), 1.0cm(3)), respectively. Plan adaptation required on average 2.6 min for the ART1 approach and yielded doses to the rectum being insignificantly different from the ART2 approach. Based on an accumulation over the total patient collective, a penalty score revealed dosimetric violations reduced by 79.2%, 75.7% and 93.2% through adaptation. CONCLUSION: Treatment plan adaptation was demonstrated to adequately restore relevant dose criteria on a daily basis. While for SAM adaptation approaches dosimetric benefits were realized through ensuring sufficient target coverage, a full re-optimization mainly improved OAR sparing which helps to guide the decision of when to apply which adaptation strategy. BioMed Central 2021-08-04 /pmc/articles/PMC8335467/ /pubmed/34348765 http://dx.doi.org/10.1186/s13014-021-01872-9 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Eckl, Miriam
Sarria, Gustavo R.
Springer, Sandra
Willam, Marvin
Ruder, Arne M.
Steil, Volker
Ehmann, Michael
Wenz, Frederik
Fleckenstein, Jens
Dosimetric benefits of daily treatment plan adaptation for prostate cancer stereotactic body radiotherapy
title Dosimetric benefits of daily treatment plan adaptation for prostate cancer stereotactic body radiotherapy
title_full Dosimetric benefits of daily treatment plan adaptation for prostate cancer stereotactic body radiotherapy
title_fullStr Dosimetric benefits of daily treatment plan adaptation for prostate cancer stereotactic body radiotherapy
title_full_unstemmed Dosimetric benefits of daily treatment plan adaptation for prostate cancer stereotactic body radiotherapy
title_short Dosimetric benefits of daily treatment plan adaptation for prostate cancer stereotactic body radiotherapy
title_sort dosimetric benefits of daily treatment plan adaptation for prostate cancer stereotactic body radiotherapy
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8335467/
https://www.ncbi.nlm.nih.gov/pubmed/34348765
http://dx.doi.org/10.1186/s13014-021-01872-9
work_keys_str_mv AT ecklmiriam dosimetricbenefitsofdailytreatmentplanadaptationforprostatecancerstereotacticbodyradiotherapy
AT sarriagustavor dosimetricbenefitsofdailytreatmentplanadaptationforprostatecancerstereotacticbodyradiotherapy
AT springersandra dosimetricbenefitsofdailytreatmentplanadaptationforprostatecancerstereotacticbodyradiotherapy
AT willammarvin dosimetricbenefitsofdailytreatmentplanadaptationforprostatecancerstereotacticbodyradiotherapy
AT ruderarnem dosimetricbenefitsofdailytreatmentplanadaptationforprostatecancerstereotacticbodyradiotherapy
AT steilvolker dosimetricbenefitsofdailytreatmentplanadaptationforprostatecancerstereotacticbodyradiotherapy
AT ehmannmichael dosimetricbenefitsofdailytreatmentplanadaptationforprostatecancerstereotacticbodyradiotherapy
AT wenzfrederik dosimetricbenefitsofdailytreatmentplanadaptationforprostatecancerstereotacticbodyradiotherapy
AT fleckensteinjens dosimetricbenefitsofdailytreatmentplanadaptationforprostatecancerstereotacticbodyradiotherapy